RxDoctor Payments Data

Gustavo Cardenas, MD

Cardiovascular Disease · Delray Beach, FLNPI 1518009331

Payments from drug & device makers

$58,639in general payments, 2019–2025

Across 867 payments — averaging $67.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$24K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$14K
  • Edwards Lifesciences$3K
  • Actelion Pharmaceuticals US, Inc.$2K
  • Biosense Webster, Inc.$1K
  • Philips North America LLC$1K
  • plus $14K from 54 others

What the payments were for

  • Consulting fees$18,00040%
  • Speaking & faculty fees$2,3005%
  • Travel & lodging$5,55412%
  • Food & beverage$19,41243%
  • Education$1530%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott102$24,204
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)36$13,621
Edwards Lifesciences26$3,118
Actelion Pharmaceuticals US, Inc.65$1,515
Biosense Webster, Inc.12$1,288
Philips North America LLC6$1,157
Penumbra, Inc.10$1,113
Johnson & Johnson74$1,065
AstraZeneca64$1,064
Amgen64$983
Abiomed25$955
Novartis47$763
Merck36$664
Amarin Pharma, Inc.24$542
Pfizer30$514
E.r. Squibb & Sons, L.L.C.24$429
Boehringer Ingelheim19$402
Heartflow, Inc.7$338
Atricure, Inc.3$314
Kestra Medical Technology Services, Inc.12$308
Boston Scientific14$307
Bard Peripheral Vascular, Inc.8$306
Biotronik Inc.6$285
Cvrx, Inc.28$285
Sanofi-aventis U.S. LLC12$258
Cardiva Medical, Inc.9$256
Medtronic(2 entities)8$224
Alnylam Pharmaceuticals Inc.9$187
Musculoskeletal Transplant Foundation Inc.1$181
W. L. Gore & Associates, Inc.1$153
Lundbeck LLC8$153
Kowa Pharmaceuticals America, Inc.8$152
Esperion Therapeutics, Inc.9$150
Bayer7$123
Impulse Dynamics (USA) Inc.2$120
Kiniksa Pharmaceuticals, Ltd.5$105
Bolton Medical Inc1$99
Chiesi USA, Inc.6$85
Arbor Pharmaceuticals, Inc.2$77
Novo Nordisk4$76
United Therapeutics Corporation3$75
Kiniksa Pharmaceuticals International, PLC2$68
Agepha Pharma FZ LLC3$63
BD2$60
Lexicon Pharmaceuticals, Inc.3$59
Asahi Intecc USA, Inc.3$59
Shockwave Medical, Inc3$45
GE HealthCare2$44
Stryker1$36
Inari Medical, Inc.1$29
Akcea Therapeutics, Inc.1$20
Venclose Inc.1$19
Regeneron Healthcare Solutions, Inc.1$19
Gilead1$18
Cardinal Health 200 LLC1$16
Biocompatibles, Inc.1$16
ZOLL Circulation Inc1$14
G Medical Diagnostic Services, Inc.1$14
Tactile Systems Technology Inc1$13
Acera Surgical, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$58,639 in reported general payments places this provider in the 85th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$2,114,394
Medicare patients
1,796
Services billed
16,509

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis22$626,436
EliquisApixaban455$559,573
XareltoRivaroxaban218$265,802
EntrestoSacubitril/Valsartan138$210,564
FarxigaDapagliflozin Propanediol66$77,176
BrilintaTicagrelor69$60,816
Repatha SureclickEvolocumab51$55,880
JardianceEmpagliflozin39$50,435
Repatha SyringeEvolocumab30$31,850
Praluent PenAlirocumab14$16,215
NexlizetBempedoic Acid/Ezetimibe12$13,433
NexletolBempedoic Acid17$10,558
Metoprolol Succinate582$6,895
Dabigatran EtexilateDabigatran Etexilate Mesylate15$5,965
Atorvastatin Calcium530$4,693

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$514$1,186,008477 claims
Johnson & JohnsonXarelto$1,065$265,802218 claims
NovartisEntresto$763$210,564138 claims
AstraZenecaFarxiga, Brilinta$1,064$137,991135 claims
Boehringer IngelheimJardiance$402$50,43539 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$150$23,99129 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Delray Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →